Nanvuranlat has entered a first-line biliary tract cancer (BTC) trial featuring a new 46-hour continuous infusion strategy alongside immune checkpoint inhibitors. The investigator-initiated study will evaluate the safety and tolerability of the novel administration approach in maintenance therapy.
Written By: Kirti Kumbhar, PharmD
Reviewed By: Pharmacally Editorial Team
J-Pharma has dosed the first patient in an investigator-initiated clinical trial evaluating nanvuranlat (JPH203) in combination with immune checkpoint inhibitors (ICIs) as maintenance therapy following first-line treatment for advanced biliary tract cancer (BTC). The study expands the clinical development of the investigational LAT1 inhibitor beyond the ongoing global Phase 3 Beacon-BTC trial, which is evaluating the drug in previously treated patients.
Trial Expands Nanvuranlat into First-Line Maintenance Setting
The newly initiated study, JON-2404-B, is being conducted at four leading Japanese cancer centers: The Cancer Institute Hospital of JFCR, National Cancer Center Hospital, National Cancer Center Hospital East, and Kanagawa Cancer Center. The Cancer Institute Hospital of JFCR is leading the investigator-initiated trial, while J-Pharma is providing operational support.
Patients enrolled in the study will receive nanvuranlat during the maintenance phase after completing approximately 18 weeks of standard first-line therapy consisting of an anti-PD-L1 antibody combined with chemotherapy. Nanvuranlat treatment will begin between Weeks 19 and 25 alongside continued immune checkpoint inhibition.
The primary objective is to evaluate the safety and tolerability of adding nanvuranlat to immune checkpoint inhibitor maintenance therapy while exploring its development potential in the first-line setting.
First-in-Class LAT1 Inhibitor Targets Cancer Metabolism
Nanvuranlat is a selective inhibitor of L-type amino acid transporter 1 (LAT1), a transporter highly expressed in many solid tumors that supplies essential amino acids required for cancer cell growth. By blocking LAT1, the investigational therapy disrupts tumor metabolism through a mechanism distinct from existing targeted therapies and immunotherapies.
The drug is considered a potential first-in-class small-molecule LAT1 inhibitor. Beyond directly inhibiting tumor growth, preclinical studies suggest nanvuranlat may also remodel the tumor immune microenvironment, increasing immune cell infiltration while reducing immunosuppressive cell populations. These biological effects provide the scientific rationale for combining the therapy with immune checkpoint inhibitors.
Earlier Clinical Data Supported Further Development
Nanvuranlat has been under clinical development since 2015. A Japanese Phase 2 placebo-controlled trial in patients with previously treated advanced biliary tract cancer reported clinically meaningful benefit with nanvuranlat monotherapy, supporting its continued development in this difficult-to-treat disease.
The investigational therapy received U.S. FDA Orphan Drug designation for biliary tract cancer in April 2022. The FDA accepted the company’s Investigational New Drug (IND) application in September 2024, followed by confirmation in May 2025 that commercial-scale manufacturing met FDA chemistry, manufacturing, and controls (CMC) quality standards.
Those milestones enabled initiation of the global Phase 3 Beacon-BTC trial in December 2025, with the first patient dosed in May 2026.
Continuous Infusion Strategy May Improve Clinical Use
Unlike previous clinical studies, the investigator-initiated trial will administer nanvuranlat as a 46-hour continuous intravenous infusion. According to J-Pharma, this administration strategy is intended to maintain adequate drug exposure while reducing the frequency of hospital visits and simplifying treatment delivery across diverse healthcare settings.
The company also noted that it holds method-of-use patents covering combination therapy with nanvuranlat and anti-PD-1 or anti-PD-L1 antibodies, strengthening the intellectual property supporting this development strategy.
Development Program Continues to Expand
With patient enrollment now underway, J-Pharma is advancing nanvuranlat through parallel clinical programs in both previously treated and first-line biliary tract cancer. The company expects the investigator-initiated study to provide early safety data for the combination approach while informing future development opportunities that could broaden the clinical use of this novel LAT1 inhibitor if ongoing studies continue to demonstrate favorable results.
Reference
About the Writer
Kirti Kumbhar (LinkedIn) is an M.Pharm graduate with experience in Quality Assurance at Lupin Limited and a strong interest in clinical research, regulatory affairs, and Trial Master File (TMF) management. She has developed knowledge of regulatory documentation, quality systems, compliance, and healthcare research through her professional experience. Passionate about clinical development and continuous learning, Kirti is committed to supporting high-quality healthcare documentation, regulatory excellence, and research-driven healthcare advancements.